entertainment -WSS

entertainment

author：entertainment 2025-09-27 12:36:09 - browse：964

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： David Sabatini, ex

knowledge

WSS

Study: Pain burden is higher in Black NFL players than white ones

Hospitals look to new technology to keep health care workers safe

Palantir health business leans on meeting customers’ needs

Surge of respiratory disease in China has likely explanation

Anthos stroke drug appears safer than common blood thinner

Retired US general questions alleged Putin, Prigozhin meeting

explore

entertainment

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Retired US general questions alleged Putin, Prigozhin meeting

Trump demands the U.S. pay no more for drugs than other countries … again

World's first CRISPR

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

In key trial, Verve's treatment lowers cholesterol levels in patients

Medicare proposal to cover medical devices draws a mixed reaction

It's time to get medical device identifiers over the finish line

Cancer drug shortages should be causing more outrage

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

hotspot

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Why medical students are struggling with mental health

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Biden launches a new push to limit health care costs

Morphosys mixed study results for blood cancer drug

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

leisure time

entertainment

knowledge

hotspot